Protalix, Chiesi Preparing to Request Accelerated FDA Approval of PRX-102 for Fabry Disease
Protalix BioTherapeutics and Chiesi Farmaceutici are planning to submit a biologics license application with the U.S. Food and Drug Administration (FDA) for PRX-102 (pegunigalsidase alfa) as a treatment for Fabry disease, the companies have announced. After several months, and a series of meetings and correspondence with…